Jupiter Neurosciences, Inc. Common Stock (JUNS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) has a cash flow conversion efficiency ratio of -20.106x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.15 Million) by net assets ($57.42K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jupiter Neurosciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read JUNS total liabilities for a breakdown of total debt and financial obligations.
Jupiter Neurosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jupiter Neurosciences, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NextEye Co. Ltd
KQ:137940
|
-0.144x |
|
TJGC Group Limited
NASDAQ:TJGC
|
-1.130x |
|
Nuvotec
KQ:060260
|
-0.075x |
|
NETUM GROUP OYJ
F:79J
|
N/A |
|
Skycorp Solar Group Limited Ordinary Shares
NASDAQ:PN
|
N/A |
|
Turk Ilac ve Serum Sanayi AS
IS:TRILC
|
0.023x |
|
Inepar S.A. Indústria e Construções
SA:INEP3
|
0.035x |
|
Sarama Resource
V:SWA
|
1.750x |
Annual Cash Flow Conversion Efficiency for Jupiter Neurosciences, Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Jupiter Neurosciences, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.17 Million | $-3.91 Million | -0.937x | -1230.76% |
| 2023-12-31 | $-5.80 Million | $-480.95K | 0.083x | -52.56% |
| 2022-12-31 | $-7.14 Million | $-1.25 Million | 0.175x | -47.85% |
| 2021-12-31 | $-5.18 Million | $-1.74 Million | 0.335x | +388.09% |
| 2020-12-31 | $-3.71 Million | $-254.78K | 0.069x | +140.91% |
| 2019-12-31 | $-5.02 Million | $-142.95K | 0.028x | -- |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phas… Read more